ATE442045T1 - Verfahren und zusammensetzungen für erhíhte tumorzell-immunität in vivo - Google Patents

Verfahren und zusammensetzungen für erhíhte tumorzell-immunität in vivo

Info

Publication number
ATE442045T1
ATE442045T1 AT95928099T AT95928099T ATE442045T1 AT E442045 T1 ATE442045 T1 AT E442045T1 AT 95928099 T AT95928099 T AT 95928099T AT 95928099 T AT95928099 T AT 95928099T AT E442045 T1 ATE442045 T1 AT E442045T1
Authority
AT
Austria
Prior art keywords
subject
cancer
methods
vivo
compositions
Prior art date
Application number
AT95928099T
Other languages
English (en)
Inventor
Habib Fakhrai
Oliver Dorigo
Robert Sobol
Original Assignee
Sidney Kimmel Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidney Kimmel Cancer Ct filed Critical Sidney Kimmel Cancer Ct
Application granted granted Critical
Publication of ATE442045T1 publication Critical patent/ATE442045T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95928099T 1994-07-18 1995-07-18 Verfahren und zusammensetzungen für erhíhte tumorzell-immunität in vivo ATE442045T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/276,694 US5772995A (en) 1994-07-18 1994-07-18 Compositions and methods for enhanced tumor cell immunity in vivo
PCT/US1995/009198 WO1996002143A1 (en) 1994-07-18 1995-07-18 Compositions and methods for enhanced tumor cell immunity in vivo

Publications (1)

Publication Number Publication Date
ATE442045T1 true ATE442045T1 (de) 2009-09-15

Family

ID=23057711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95928099T ATE442045T1 (de) 1994-07-18 1995-07-18 Verfahren und zusammensetzungen für erhíhte tumorzell-immunität in vivo

Country Status (10)

Country Link
US (4) US5772995A (de)
EP (1) EP0771147B1 (de)
JP (2) JP3839843B2 (de)
AT (1) ATE442045T1 (de)
CA (1) CA2195334C (de)
DE (1) DE69535999D1 (de)
DK (1) DK0771147T3 (de)
ES (1) ES2334407T3 (de)
PT (1) PT771147E (de)
WO (1) WO1996002143A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
WO1998049268A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
US8034332B2 (en) * 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
EP2295065B1 (de) * 1998-02-20 2013-10-09 The University of Miami Modifizierter Hitzeschockprotein-Antigenpeptid-Komplex
DE69919869T2 (de) * 1998-06-10 2005-09-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Stimulierung des immunsystems
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US20030190322A1 (en) * 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
WO2001072331A1 (en) * 2000-03-31 2001-10-04 Vaccine Chip Technology Aps Immunostimulating properties of a fragment of tgf-beta
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
PT1267945E (pt) * 2000-03-31 2011-12-28 Novarx Células geneticamente modificadas que expressam um inibidor de ftc-beta, sendo essas células, células de cancro de pulmão
CA2409765A1 (en) 2000-05-10 2001-11-15 David A. Sirbasku Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2002079391A2 (en) * 2001-04-02 2002-10-10 Cytoprint, Inc. Methods and apparatus for discovering, identifying and comparing biological activity mechanisms
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
US20030044393A1 (en) * 2001-07-06 2003-03-06 Annie-Chen Tran Method for increasing tumor cell immunogenicity using heat shock protein
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
US20030180301A1 (en) * 2002-01-22 2003-09-25 Shaf Keshavjee Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
WO2005003291A2 (en) * 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
EP1556071B1 (de) * 2002-10-25 2011-01-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
CA2526690C (en) * 2003-05-23 2014-01-14 Board Of Regents The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
AU2005218759B2 (en) * 2004-02-27 2009-07-16 Antisense Pharma Gmbh Pharmaceutical composition
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US20090004182A1 (en) * 2004-10-13 2009-01-01 The Ohio State University Research Foundation Methods to Treat or Prevent Viral-Associated Lymphoproliferative Disorders
EP1861123A2 (de) * 2005-02-17 2007-12-05 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Synergistische wirkung der tgf-beta-blockade und immunogene mittel auf tumoren
US20060281702A1 (en) * 2005-05-18 2006-12-14 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate aptamers for RNases
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
EP1920781B1 (de) * 2006-11-10 2015-03-04 Glycotope GmbH Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren
EP2101812A1 (de) * 2006-12-20 2009-09-23 Novarx Universeller tumorzellenimpfstoff für antikrebstherapie- und prophylaxeverwendung
JP2011513399A (ja) 2008-03-03 2011-04-28 ザ ユニバーシティー オブ マイアミ 同種癌細胞による免疫療法
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
EP2835053B1 (de) 2010-03-12 2016-04-27 Genzyme Corporation Kombinationstherapie zur Behandlung von Brustkrebs
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
US20140120111A1 (en) 2011-05-19 2014-05-01 The Johns Hopkins University Treatment of autoimmune disorders and infections using antagonists of sgk1 activity
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
US20150037357A1 (en) * 2011-12-23 2015-02-05 Novarx Corporation Immune stimulation/metabolic inhibition as antitumor therapy
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
US9879227B2 (en) 2012-11-09 2018-01-30 Marco Archetti Diffusible factors and cancer cells
JPWO2015064768A1 (ja) 2013-10-31 2017-03-09 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
US11230719B2 (en) 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
MX2017010159A (es) 2015-02-06 2017-12-18 Heat Biologics Inc Vector que expresa conjuntamente vacunas y moléculas coestimuladoras.
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
EP3774912A1 (de) * 2018-04-10 2021-02-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Kombination von nah-infrarot-fotoimmunotherapie gegen krebszellen und wirtsimmunaktivierung
IL293446A (en) * 2019-12-03 2022-07-01 Neuvogen Inc Tumor cell vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
DE69230506T2 (de) * 1991-10-25 2000-06-21 Sidney Kimmel Cancer Center Sa Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
EP1008649B1 (de) 1993-04-30 2003-03-26 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
JP3555952B2 (ja) * 1993-04-30 2004-08-18 バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
CA2171211A1 (en) * 1993-09-07 1995-03-16 Robert E. Sobol Haplotype-matched cytokine-secreting cells and methods of using to stimulate an immune response
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells

Also Published As

Publication number Publication date
US8444964B2 (en) 2013-05-21
AU711730B2 (en) 1999-10-21
US5772995A (en) 1998-06-30
US6447769B1 (en) 2002-09-10
US20020192199A1 (en) 2002-12-19
US6120763A (en) 2000-09-19
JP2001526622A (ja) 2001-12-18
JP2006217924A (ja) 2006-08-24
JP3839843B2 (ja) 2006-11-01
DE69535999D1 (de) 2009-10-22
EP0771147A1 (de) 1997-05-07
EP0771147A4 (de) 2004-06-16
WO1996002143A1 (en) 1996-02-01
DK0771147T3 (da) 2010-01-04
EP0771147B1 (de) 2009-09-09
ES2334407T3 (es) 2010-03-09
CA2195334A1 (en) 1996-02-01
AU3217895A (en) 1996-02-16
CA2195334C (en) 2013-03-19
PT771147E (pt) 2009-11-25

Similar Documents

Publication Publication Date Title
DE69535999D1 (de) Verfahren und zusammensetzungen für erhöhte tumorzell-immunität in vivo
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
TR200000015T2 (tr) Bileşikler ve metodlar
EP0283675A3 (en) Dental plaque and dental caries inhibiting agent and compositions containing such an agent
AU579595B2 (en) Enzyme-resistant immunomodulatory peptides
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
PL302304A1 (en) Peptides of body organs protecting action, method of obtaining them and their application in therapy
ZA200005413B (en) Cholesterol sulfate compositions for enhancement of stratum corneum function.
IL123642A0 (en) Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration
ATE81467T1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
DE69606321T2 (de) Stabilisiertes sonnenschutzmittel
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
DE3371076D1 (en) Substituted tert. butanol derivatives, method for their preparation and antimycotic agents containing them
DE69534753D1 (de) Nierenpolycystose-gen
NZ316609A (en) Lyophilized thioxanthenone antitumor agents
HUT75529A (en) Use of dimeticone for treating constipation
ATE305785T1 (de) Cd45 hemmer
PT930877E (pt) D-metionina para reduzir a toxicidade de compostos antitumorais contendo platina
MX9705433A (es) Antagonistas de la hormona estimulante alfa-melanocito y metodos basados sobre los mismos.
GB2264058A (en) Methods and compositions for amelioration of skin wrinkles
UA27781C2 (uk) Спосіб лікування метастазів пухлин
MY102564A (en) An indole derivative

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0771147

Country of ref document: EP